NR2F1 and melanoma: Tiago and colleagues’ analysis of published single-cell and bulk transcriptomics datasets confirmed that NR2F1 was highly expressed in BRAFi + MEKi–treated patients with melanoma and BRAF-mutant melanoma patient–derived xenografts, particularly in invasive MRD, as well as in preclinical cell models.